Biotech | May 01, 2022
Inmagene receives USFDA's IND clearance for ox40 antagonist
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
South Carolina’s largest health system adopts Philips software solutions for patient monitoring and enterprise imaging, helping to drive interoperability and data analytics, and deliver on Quadruple Aim
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
TSCS appeals to the Govt. of Telangana to release a G.O for mandatory antenatal test - HbA2 for every pregnant woman to help prevent the birth of Thalassemia Major Children for the well-being of their family & Telangana State
Beyond the technical leadership from F1, the collaboration will bring a specific focus on the people dimension of high performance
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
The minister was speaking at the 7th International conference on Pharma and Medical Devices sector; chairs two roundtable conferences with the CEOs
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Subscribe To Our Newsletter & Stay Updated
